180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement
10 avr. 2023 16h30 HE
|
180 Life Sciences Corp.
PALO ALTO, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the...
180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private Placement
05 avr. 2023 13h00 HE
|
180 Life Sciences Corp.
PALO ALTO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced that it...
180 Life Sciences Announces Presentation at the Gordon Conference
27 févr. 2023 08h30 HE
|
180 Life Sciences Corp.
PALO ALTO, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that Professor Jagdeep Nanchahal has been selected...
180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren’s Disease Treatment and Application
23 févr. 2023 07h30 HE
|
180 Life Sciences Corp.
PALO ALTO, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the United States Patent and Trademark Office...
180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder Trial
22 févr. 2023 16h30 HE
|
180 Life Sciences Corp.
PALO ALTO, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced closure to recruitment of men and women across...
180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren’s Disease
25 janv. 2023 08h45 HE
|
180 Life Sciences Corp.
PALO ALTO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced the publication of a review entitled ‘Treatments...
180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom
17 janv. 2023 08h00 HE
|
180 Life Sciences Corp.
PALO ALTO, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company has engaged Kinexum, a strategic...
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
05 janv. 2023 08h30 HE
|
180 Life Sciences Corp.
PALO ALTO, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on January 4,...
180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s Disease
04 janv. 2023 08h30 HE
|
180 Life Sciences Corp.
PALO ALTO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced the publication of a review entitled ‘Dupuytren’s...
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders
29 déc. 2022 08h30 HE
|
180 Life Sciences Corp.
PALO ALTO, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Dear Fellow Shareholder, As we come to the end of 2022, I am pleased to provide an update for our shareholders. In keeping with good corporate...